CARMIL1

Across TCGA pan-cancer cohorts, CARMIL1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of CARMIL1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CARMIL1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CARMIL1 is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where CARMIL1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CARMIL1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	−0.316	<.001	12	view →
LUAD	Female	III,IV	−0.552	<.001	9	view →
LSCC	Female	All	−0.399	<.001	8	view →
PDAC	All	III,IV	+0.259	.012	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

CARMIL1–CCRCC

Open the CCRCC breakdown →